Bristol Myers Squibb Company BMY
- Market cap
- $125.9B
- P/E
- 13.8×
Follow BMY
Bristol Myers Squibb Company (BMY) EV/Sales
As of 25 September 2026, Bristol Myers Squibb Company (BMY) trades at a EV/Sales of 3.3×. Over the past ten years it has ranged from 2.5× (October 2025) to 7.5× (June 2016); the current reading is higher than 25% of that period. That is below the Drug Manufacturers General industry median of 4.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Annual
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.0× | (5.85%) |
| FY2024 | 3.2× | 4.63% |
| FY2023 | 3.0× | (23.82%) |
| FY2022 | 4.0× | 11.33% |
| FY2021 | 3.6× | (12.97%) |
| FY2020 | 4.1× | (23.60%) |
| FY2019 | 5.4× | 45.54% |
| FY2018 | 3.7× | (24.64%) |
| FY2017 | 4.9× | (4.33%) |
| FY2016 | 5.1× | (27.42%) |
Quarterly
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.0× | (6.35%) |
| Mar 2026 | 3.3× | 8.67% |
| Dec 2025 | 3.0× | 15.59% |
| Sep 2025 | 2.6× | (4.88%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SNY Sanofi compare | 2.0× |
| GSK GSK PLC Sponsored ADR compare | 2.7× |
| BMY Bristol Myers Squibb Company | 3.3× |
| PFE Pfizer Inc. compare | 3.4× |
| NVO Novo Nordisk A/S compare | 3.6× |
| AZN AstraZeneca PLC compare | 4.6× |
| NVS Novartis AG compare | 5.6× |
| GILD Gilead Sciences, Inc. compare | 6.9× |
| AMGN Amgen Inc. compare | 7.0× |
| Drug Manufacturers General industry median | 4.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.2× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on BMY
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement